{"product_id":"unither-balanced-scorecard","title":"United Therapeutics Balanced Scorecard","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Balanced Scorecard\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis United Therapeutics Balanced Scorecard Analysis gives you a clear, company-specific view of the firm’s financial, customer, internal process, and learning and growth priorities. The page already includes a real preview of the actual analysis, so you can see exactly what the content looks like before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eB\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eenefits\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics is a concentrated story: 2025 sales still depend on a small set of pulmonary hypertension therapies, while its longer-term upside sits in a few late-stage programs. That makes pipeline focus a real scorecard issue, because one Phase 3 readout can shift valuation fast. Management should track milestone hits, not just quarterly revenue.\u003c\/p\u003e\n\u003cp\u003eIn 2025, that discipline matters even more as the company keeps most capital tied to rare-disease growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Discipline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics can use its scorecard to balance commercial cash flow with research spend and factory buildout, so it knows when to push late-stage trials, organ manufacturing, or delivery-system upgrades. That matters in biotech, where payback can take years and one bad capital call can hurt returns. Cash discipline also helps management protect liquidity while funding growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, United Therapeutics can judge patient access by starts, refills, and discontinuations across its chronic, specialty therapies. Those metrics show whether patients stay on therapy and whether support programs reduce friction, which matters as much as new prescriptions in rare disease. With access and persistence tied to long-term revenue, even small refill drops can signal a growth problem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturing Control is a clear benefit for United Therapeutics because its 2025 work spans drug development, delivery systems, and regenerative medicine, where small process misses can cause big scale-up delays. A Balanced Scorecard can track four key points: batch success, yield, compliance, and tech-transfer readiness, so management sees quality issues early. That matters more as the company pushes into complex manufacturing, where clean handoffs and stable runs protect both output and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMilestone visibility gives United Therapeutics leadership and investors one common view of Phase 2, Phase 3, and filing progress, so clinical work, FDA steps, and launch prep can be tracked against budget and time. In FY2025, that matters because one missed gate can ripple into cash use and revenue timing in a science-led model built on a small set of big programs. Clear checkpoints reduce drift and force faster fixes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited Therapeutics’ FY2025 Scorecard: Tighter Cash, Faster Trials, Better Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor United Therapeutics, the benefit of a Balanced Scorecard in FY2025 is clearer cash control, faster trial gates, and tighter manufacturing discipline across a few high-value programs. It helps management tie R\u0026amp;D spend to milestones, so the company can protect margins while funding growth. One clean view beats scattered reports.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBenefit\u003c\/th\u003e\n\u003cth\u003eFY2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone visibility\u003c\/td\u003e\n\u003ctd\u003e4 key scorecard tracks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing control\u003c\/td\u003e\n\u003ctd\u003eBatch, yield, compliance, transfer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital discipline\u003c\/td\u003e\n\u003ctd\u003eCash tied to trial gates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIt also helps leaders spot patient-dropoff risk early, so refill and discontinuation trends can be fixed before they hurt revenue. That matters more in rare disease, where small changes can move results fast.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes United Therapeutics’s strategic performance through the Balanced Scorecard’s financial, customer, internal process, and learning and growth lenses\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a quick Balanced Scorecard view of United Therapeutics to simplify strategy gaps, performance tracking, and decision-making.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erawbacks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong Horizon\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical programs and organ-manufacturing platforms can take 5-10+ years to create value, so a quarterly scorecard can reward near-term optics over long-duration science. For United Therapeutics, that is risky because its 2025 value still depends on pipeline milestones and organ-manufacturing scale-up, not just near-term revenue. A short scorecard can push managers to favor visible wins over the slower work that builds durable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetric Noise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMetric noise is a real drawback at United Therapeutics because 2025 results mix hard-to-compare signals: patient benefit, platform quality, and regulatory odds do not fit neatly into a few KPIs. A single trial update or FDA step can matter more than quarterly revenue, which was $2.8 billion in 2024 and still leaves 2025 value creation tied to pipeline timing, not just reported sales. So the scorecard can overstate short-term swings and understate long-run progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSparse Benchmarks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of FY2025, United Therapeutics still operated in two thin-benchmark arenas: pulmonary hypertension and organ manufacturing. With few direct peers, scorecard targets are harder to calibrate, so managers must lean more on internal trend lines than peer rank.\u003c\/p\u003e\n\u003cp\u003eThat weakens comparability on growth, margin, and R\u0026amp;D efficiency, especially when the company’s biology-heavy pipeline and organ work do not match standard biotech comps.\u003c\/p\u003e\n\u003cp\u003eIn practice, that can make a 10% revenue target or a 200 bp margin move look either too easy or too harsh, because the peer set is too small to anchor it cleanly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eData burden is a real drag for United Therapeutics because it has to track trial endpoints, manufacturing yields, patient access, and finance metrics across a mix of programs and products. In 2025, the company still had to manage a small but complex portfolio, so each new study or supply change adds more reporting and audit work. For a specialized biotech, that overhead can pull staff time away from R\u0026amp;D and slow decisions when data needs to be reconciled across functions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBinary Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor United Therapeutics, binary risk means a scorecard can look fine right up to an FDA or Phase 3 shock. In biotech, one late-stage miss can erase months of clean metrics and hit the stock harder than modest 2025 revenue or margin gains can support.\u003c\/p\u003e\n\u003cp\u003eThat is the flaw: dashboards track trend, but they do not price in a sudden trial failure, CRL, or label setback. One bad readout can overwhelm several good scorecard cells.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited Therapeutics Faces 2025 Binary Trial Risk and Weak Benchmarking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics’ scorecard is vulnerable to long trial cycles, so FY2025 can still look weak even when the pipeline is advancing. The 2025 risk is binary: one FDA or Phase 3 setback can outweigh several clean KPI lines. It also faces thin peer sets, so growth and margin targets are harder to benchmark.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrawback\u003c\/th\u003e\n\u003cth\u003eFY2025 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong R\u0026amp;D lag\u003c\/td\u003e\n\u003ctd\u003eSlow value capture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFew peers\u003c\/td\u003e\n\u003ctd\u003eWeak benchmarking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBinary biotech risk\u003c\/td\u003e\n\u003ctd\u003eSharp scorecard swings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eUnited Therapeutics Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual United Therapeutics Balanced Scorecard analysis document you’ll receive after purchase—no sample, no placeholders, just the full report. The preview below is taken directly from the final file, so what you see is what you get. Once purchased, you’ll unlock the complete, detailed version ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53675235344726,"sku":"unither-balanced-scorecard","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/unither-balanced-scorecard.webp?v=1778901918","url":"https:\/\/balancedscorecardexamples.com\/products\/unither-balanced-scorecard","provider":"Balanced Scorecard","version":"1.0","type":"link"}